PERRIGO Co plc: insider trades · United States · SEC (Form 4)

About PERRIGO Co plc

Perrigo Company plc (ticker: PRGO) is a U.S.-listed stock traded on the NYSE, making it relevant for investors following SEC Form 4 insider transactions and U.S. consumer-health equities. Although Perrigo is incorporated in Ireland and its corporate headquarters are in Dublin, its investor base, disclosure profile, and operating footprint are closely tied to the United States, where the company maintains a major manufacturing and commercial presence. The business traces its roots back to 1887, when Luther Perrigo began packaging and distributing patented medicines and household items for country stores. That heritage still shapes the company’s identity as a scale player in affordable, widely distributed self-care products. ([perrigo.com](https://www.perrigo.com/history-convenient-healthy-solutions?utm_source=openai)) Today, Perrigo is positioned as a leading provider of consumer self-care products and over-the-counter health and wellness solutions. Its portfolio spans OTC medicines, oral care, infant formula, women’s health, skincare, digestive health, smoking cessation, and related self-care categories. SEC filings show that Perrigo has historically organized its business around consumer self-care segments, and more recent reporting reflects a continuing push to align the company’s structure more tightly with its commercial operating model. This matters because Perrigo’s economics depend on breadth of category coverage, regulatory execution, and manufacturing scale across both private-label and branded products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001944048/000194404825000118/final2024annualreport.pdf?utm_source=openai)) Competitive positioning is one of Perrigo’s key strengths. The company has described itself as the largest U.S. manufacturer of OTC self-care products by volume, supported by 11 U.S. manufacturing facilities and a high domestic sourcing and production mix. That scale gives Perrigo leverage with retailers, helps protect supply reliability, and supports its store-brand leadership in categories where price, availability, and trust are critical. ([investor.perrigo.com](https://investor.perrigo.com/2025-05-07-Perrigo-Reports-First-Quarter-2025-Financial-Results-From-Continuing-Operations?utm_source=openai)) Its product set includes everyday essentials rather than prescription drugs: cough, cold and allergy treatments; pain care; digestive health; oral care; baby care; women’s health; and other self-care categories. Perrigo also has exposure to infant nutrition, which has been an operational focus in recent periods. A notable consumer-facing milestone was the U.S. launch of Opill®, the first over-the-counter oral contraceptive in the country, rolled out through a large retail network. This launch highlighted Perrigo’s ability to combine scientific, regulatory, and commercial capabilities in a high-visibility category. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/cy24q1ex991pressrelease.htm?utm_source=openai)) Recent developments suggest a company in transition rather than in a static defensive profile. In 2025, Perrigo announced strategic reviews of its infant formula and oral care businesses and signed an agreement to divest its Dermacosmetics business; that transaction was completed in 2026. Management has also emphasized a simplification agenda, a new operating model, and cost-savings initiatives aimed at stabilizing performance and improving long-term margins. For investors, PRGO combines defensive consumer-health exposure with a meaningful portfolio-repositioning story. ([investor.perrigo.com](https://investor.perrigo.com/2025-11-05-Perrigo-to-Conduct-Strategic-Review-of-its-Infant-Formula-Business?utm_source=openai))